A detailed history of Amalgamated Bank transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 3,147 shares of NTLA stock, worth $37,921. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,147
Previous 3,147 -0.0%
Holding current value
$37,921
Previous $70,000 7.14%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$20.02 - $27.22 $2,822 - $3,838
141 Added 4.69%
3,147 $70,000
Q1 2024

Apr 23, 2024

SELL
$23.82 - $32.8 $132,701 - $182,728
-5,571 Reduced 64.95%
3,006 $83,000
Q4 2023

Feb 06, 2024

SELL
$23.16 - $32.34 $17,022 - $23,769
-735 Reduced 7.89%
8,577 $262,000
Q3 2023

Nov 08, 2023

BUY
$31.62 - $45.78 $6,924 - $10,025
219 Added 2.41%
9,312 $294,000
Q2 2023

Aug 11, 2023

SELL
$34.58 - $46.03 $58,371 - $77,698
-1,688 Reduced 15.66%
9,093 $370,000
Q1 2023

May 02, 2023

SELL
$33.3 - $44.82 $78,055 - $105,058
-2,344 Reduced 17.86%
10,781 $402,000
Q4 2022

Feb 10, 2023

BUY
$33.21 - $62.69 $58,881 - $111,149
1,773 Added 15.62%
13,125 $458,000
Q3 2022

Nov 09, 2022

BUY
$53.92 - $71.7 $11,970 - $15,917
222 Added 1.99%
11,352 $635,000
Q2 2022

Aug 15, 2022

SELL
$38.49 - $76.21 $11,162 - $22,100
-290 Reduced 2.54%
11,130 $576,000
Q1 2022

Jun 30, 2022

SELL
$58.27 - $118.99 $49,820 - $101,736
-855 Reduced 6.97%
11,420 $830,000
Q4 2021

Feb 15, 2022

BUY
$100.76 - $138.36 $3,022 - $4,150
30 Added 0.24%
12,275 $1.45 Million
Q3 2021

Oct 29, 2021

BUY
$132.37 - $176.78 $24,091 - $32,173
182 Added 1.51%
12,245 $1.64 Million
Q2 2021

Aug 16, 2021

BUY
$60.88 - $161.91 $258,922 - $688,603
4,253 Added 54.46%
12,063 $1.95 Million
Q1 2021

May 13, 2021

SELL
$46.59 - $83.68 $1,164 - $2,092
-25 Reduced 0.32%
7,810 $627,000
Q4 2020

Feb 12, 2021

BUY
$18.83 - $63.53 $147,533 - $497,757
7,835 New
7,835 $426,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $916M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.